- Home
- APLT vs AGEN Comparison
APLT vs AGEN Comparison
Compare APLT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- AGEN
- Stock Information
- Founded
- APLT 2016
- AGEN 1994
- Country
- APLT United States
- AGEN United States
- Employees
- APLT N/A
- AGEN N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLT Health Care
- AGEN Health Care
- Exchange
- APLT Nasdaq
- AGEN Nasdaq
- Market Cap
- APLT 37.5M
- AGEN 38.1M
- IPO Year
- APLT 2019
- AGEN 2000
- Fundamental
- Price
- APLT $0.33
- AGEN $2.08
- Analyst Decision
- APLT Buy
- AGEN Buy
- Analyst Count
- APLT 7
- AGEN 4
- Target Price
- APLT $6.10
- AGEN $8.00
- AVG Volume (30 Days)
- APLT 2.3M
- AGEN 439.0K
- Earning Date
- APLT 04-14-2025
- AGEN 05-06-2025
- Dividend Yield
- APLT N/A
- AGEN N/A
- EPS Growth
- APLT N/A
- AGEN N/A
- EPS
- APLT N/A
- AGEN N/A
- Revenue
- APLT $455,000.00
- AGEN $103,463,000.00
- Revenue This Year
- APLT $3,031.87
- AGEN $4.03
- Revenue Next Year
- APLT $312.01
- AGEN $5.57
- P/E Ratio
- APLT N/A
- AGEN N/A
- Revenue Growth
- APLT N/A
- AGEN N/A
- 52 Week Low
- APLT $0.30
- AGEN $1.38
- 52 Week High
- APLT $10.62
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- APLT 36.05
- AGEN 57.30
- Support Level
- APLT $0.30
- AGEN $1.60
- Resistance Level
- APLT $0.38
- AGEN $1.83
- Average True Range (ATR)
- APLT 0.05
- AGEN 0.19
- MACD
- APLT -0.00
- AGEN 0.08
- Stochastic Oscillator
- APLT 17.19
- AGEN 94.59
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).